Botulinum toxin, produced by the anaerobic bacterium Clostridium botulinum, is the most potent acute toxin known. While it causes the rare but often fatal disease botulism by blocking acetylcholine release at the neuromuscular junction, it has emerged as a valuable therapeutic agent. The toxin comprises a heavy chain responsible for binding and internalization, and a light chain with enzymatic activity that prevents neurotransmitter release. There is no cure for botulism itself; antitoxin and supportive care remain the only treatments. However, botulinum toxin's high potency and specificity make it ideal for treating involuntary muscle disorders. It has become the treatment of choice for benign essential blepharospasm and is effective for various focal dystonias including spasmodic torticollis, hemifacial spasm, and Meige syndrome. It also shows promise for writer's cramp, task-specific hand disorders, spasticity, and tremor. Side effects are generally minor and localized. Long-term safety appears good, though some patients develop neutralizing antibodies, rendering further treatment ineffective. Understanding the toxin's molecular mechanisms offers potential for developing new therapeutics targeting motor nerves or modulating neurotransmitter release.

Key findings

• Botulinum toxin blocks acetylcholine release by cleaving specific synaptic vesicle proteins through zinc endopeptidase activity of its light chain.
• Botulinum toxin type A has become the treatment of choice for benign essential blepharospasm and is effective for multiple focal dystonia conditions.
• Therapeutic botulinum toxin produces temporary muscular weakness through chemical denervation, requiring repeat injections for sustained symptom control.
• Side effects are generally minor and localized, with no documented adverse systemic effects in long-term treatment, though some patients develop neutralizing antibodies.
• The toxin's structure and mechanism offer potential for developing novel therapeutics that target motor nerves or modulate other neurotransmitter systems.